stryker

Clinical cases collection



OptaBlate®
bone tumor
ablation system

Physician

Dr. Josh Bautista

Community Hospital
Munster, Indiana

Clinical case

Patient: Female, 76

Level: T7

Reason: Vertebral tumor and compression fracture with wedge deformity

Case type: OptaBlate 20mm and iVAS Elite 10g 15mm

Visual analog scale



Case presentation

A 76-year-old female, with previously diagnosed and treated lung cancer, presented with a painful vertebral fracture and metastatic lesion in the T7 vertebral body. The patient had already reached their maximum dose of radiation and was not a candidate for radiation of the T7 lesion.

The patient reported severe back pain with a VAS score of 7/10 at consult and was referred to Interventional Radiology for evaluation. A PET and MRI scan revealed a suspected lytic lesion at the fractured site. The patient underwent a biopsy of the lesion, bone tumor ablation, and balloon kyphoplasty in a single session.

The procedure was successfully completed in 45 minutes using a unilateral approach through a single pedicle to gain access to the T7 vertebral body. An OptaBlate 20mm ablation probe was used to ablate the vertebral body, before stabilizing the bone with a balloon kyphoplasty using iVAS Elite and 3.5cc of VertaPlex HV bone cement.

Prior to the procedure the patient reported a pain score of 7/10 on the VAS scale. On the day of the procedure, at the time of discharge, the patient reported pain was reduced to a 0/10.

Pre-op images



Pre-op CT (axial view)



Pre-op CT (axial view)

Surgical procedure



Procedure fluoro (lateral view)

Post-op images



Post-op fluoro (lateral view)



Post-op fluoro (AP view)

stryker

Interventional Spine

Bone cement: Serious adverse events, some with fatal outcome, associated with the use of bone cements for vertebroplasty, kyphoplasty and sacroplasty include myocardial infarction, cardiac arrest, cerebrovascular accident, pulmonary embolism and cardiac embolism. Although it is rare, some adverse events have been known to occur beyond one year post-operatively. Additional risks exist with the use of bone cement. Please see the IFU for a complete list of potential risks.

This document is intended solely for the use of healthcare professionals. A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. We do not dispense medical advice and recommend that physicians be trained in the use of any particular product before using it.

The information presented is intended to demonstrate Stryker's products. A physician must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any of Stryker's products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your representative if you have questions about the availability of Stryker's products in your area.

Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: iVAS, OptaBlate, Stryker and VertaPlex. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo.

IVS-GSNPS-STUD-1358770_REV-0

Stryker Instruments
1941 Stryker Way
Portage, MI 49002

strykerivs.com